S
Sha-Sha Cheng
Researcher at University of Macau
Publications - 11
Citations - 172
Sha-Sha Cheng is an academic researcher from University of Macau. The author has contributed to research in topics: Chemistry & Cancer research. The author has an hindex of 3, co-authored 8 publications receiving 47 citations.
Papers
More filters
Journal ArticleDOI
The design and development of covalent protein-protein interaction inhibitors for cancer treatment.
TL;DR: This review will highlight the design and development of therapeutic agents targeting PPIs for cancer therapy and suggest that there is a reduced risk for the development of drug resistance against covalent drugs, which is a major challenge in areas such as oncology and infectious diseases.
Journal ArticleDOI
A long-lived luminogenic iridium(III) complex for acetylacetone detection in environmental samples
Wanhe Wang,Wanhe Wang,Tsan-Ling Yung,Sha-Sha Cheng,Feng Chen,Jin-Biao Liu,Jin-Biao Liu,Chung-Hang Leung,Dik-Lung Ma +8 more
TL;DR: Because probe 8 is very easily prepared and modified compared with existing Acac luminescence probes, it serves as an ideal starting point to develop next-generation luminogenic probes for monitoring Acac in environmental and biological systems.
Journal ArticleDOI
Development of Natural Product-Conjugated Metal Complexes as Cancer Therapies.
TL;DR: This review aims to highlight the recent examples of natural product-conjugated metal complexes as cancer therapies with enhanced selectivity and efficacy.
Journal ArticleDOI
Inhibition of the CDK9‒cyclin T1 protein‒protein interaction as a new approach against triple-negative breast cancer
Sha-Sha Cheng,Yuan-Qing Qu,Jia Wu,Guan-Jun Yang,Guan-Jun Yang,Hao Liu,Wanhe Wang,Wanhe Wang,Qi Huang,Feng Chen,Guodong Li,Chun-Yuen Wong,Vincent Kam Wai Wong,Dik-Lung Ma,Chung-Hang Leung +14 more
TL;DR: In this paper, the authors designed and generated a library of metal complexes bearing the 7-chloro-2-phenylquinoline CˆN ligand and tested their activity against the CDK9-cyclin T1 PPI.
Journal ArticleDOI
Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells
TL;DR: This work identifies a tetrahydroisoquinoline derivative (compound 1) as a potent and selective CDK9-cyclin T1 inhibitor via virtual screening and provides insight into the role of the CDK 9-cyclIn T1 PPI on EMT and CSCs and highlights the feasibility and significance of targetingCDK9 for the treatment of TNBC.